Loading…

Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines

Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorino...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2016-09, Vol.59 (18), p.8233-8262
Main Authors: Yang, Eugene Guorong, Mustafa, Nurulhuda, Tan, Eng Chong, Poulsen, Anders, Ramanujulu, Pondy Murugappan, Chng, Wee Joo, Yen, Jeffrey J. Y, Dymock, Brian W
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623
cites cdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623
container_end_page 8262
container_issue 18
container_start_page 8233
container_title Journal of medicinal chemistry
container_volume 59
creator Yang, Eugene Guorong
Mustafa, Nurulhuda
Tan, Eng Chong
Poulsen, Anders
Ramanujulu, Pondy Murugappan
Chng, Wee Joo
Yen, Jeffrey J. Y
Dymock, Brian W
description Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is 50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.
doi_str_mv 10.1021/acs.jmedchem.6b00157
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1823031069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1823031069</sourcerecordid><originalsourceid>FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</originalsourceid><addsrcrecordid>eNp9kd1u1DAQhS0EokvhDRDy5fYii3-T9HK7W7ptVwIJuI4cZ9KdKrGX2AHtq_F0eP96yc1Y1nznjD2HkI-czTgT_LOxYfbcQ2M30M_ymjGui1dkwrVgmSqZek0mjAmRiVzIC_IuhGfGmORCviUXotCKS11MyN8lBHxy1LiGft-5uEnXQH1LH4wbA31EZwJQQacP80dxdcBWGKJ3QJdgLMRutwemq-V8cUVvMGzBYouW3rsN1hj9EOhNIhrqHf1m7IARHdYHo9vf2ICzsB-3HE2X-nHzx-zOWkwSdHQFvYm-809oE7OArqNrdBDekzet6QJ8OJ2X5OeX2x-LVbb-ene_mK8zI1UZM85yZYTkDeOgSi1V0bZ5LkwLOpVag2SWq-tUC95oqUstOIAqjJTC8LS8SzI9-m4H_2uEEKseg03PMA78GCpeCpkWy_LrhKojagcfwgBttR2wN8Ou4qzap1al1KpzatUptST7dJow1qn3IjrHlAB2BA5yPw4uffj_nv8AAjel_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1823031069</pqid></control><display><type>article</type><title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</title><source>American Chemical Society:Jisc Collections:American Chemical Society Read &amp; Publish Agreement 2022-2024 (Reading list)</source><creator>Yang, Eugene Guorong ; Mustafa, Nurulhuda ; Tan, Eng Chong ; Poulsen, Anders ; Ramanujulu, Pondy Murugappan ; Chng, Wee Joo ; Yen, Jeffrey J. Y ; Dymock, Brian W</creator><creatorcontrib>Yang, Eugene Guorong ; Mustafa, Nurulhuda ; Tan, Eng Chong ; Poulsen, Anders ; Ramanujulu, Pondy Murugappan ; Chng, Wee Joo ; Yen, Jeffrey J. Y ; Dymock, Brian W</creatorcontrib><description>Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is &lt;100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and &gt;50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/acs.jmedchem.6b00157</identifier><identifier>PMID: 27541357</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Apoptosis - drug effects ; Bridged-Ring Compounds - chemistry ; Bridged-Ring Compounds - pharmacology ; Cell Line, Tumor ; Cell Proliferation - drug effects ; Hematologic Neoplasms - drug therapy ; Hematologic Neoplasms - metabolism ; Histone Deacetylase Inhibitors - chemistry ; Histone Deacetylase Inhibitors - pharmacology ; Humans ; Janus Kinase 2 - antagonists &amp; inhibitors ; Models, Molecular ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Pyrimidines - chemistry ; Pyrimidines - pharmacology ; Signal Transduction - drug effects</subject><ispartof>Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8233-8262</ispartof><rights>Copyright © 2016 American Chemical Society</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</citedby><cites>FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27541357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Eugene Guorong</creatorcontrib><creatorcontrib>Mustafa, Nurulhuda</creatorcontrib><creatorcontrib>Tan, Eng Chong</creatorcontrib><creatorcontrib>Poulsen, Anders</creatorcontrib><creatorcontrib>Ramanujulu, Pondy Murugappan</creatorcontrib><creatorcontrib>Chng, Wee Joo</creatorcontrib><creatorcontrib>Yen, Jeffrey J. Y</creatorcontrib><creatorcontrib>Dymock, Brian W</creatorcontrib><title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is &lt;100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and &gt;50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</description><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Bridged-Ring Compounds - chemistry</subject><subject>Bridged-Ring Compounds - pharmacology</subject><subject>Cell Line, Tumor</subject><subject>Cell Proliferation - drug effects</subject><subject>Hematologic Neoplasms - drug therapy</subject><subject>Hematologic Neoplasms - metabolism</subject><subject>Histone Deacetylase Inhibitors - chemistry</subject><subject>Histone Deacetylase Inhibitors - pharmacology</subject><subject>Humans</subject><subject>Janus Kinase 2 - antagonists &amp; inhibitors</subject><subject>Models, Molecular</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Pyrimidines - chemistry</subject><subject>Pyrimidines - pharmacology</subject><subject>Signal Transduction - drug effects</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><recordid>eNp9kd1u1DAQhS0EokvhDRDy5fYii3-T9HK7W7ptVwIJuI4cZ9KdKrGX2AHtq_F0eP96yc1Y1nznjD2HkI-czTgT_LOxYfbcQ2M30M_ymjGui1dkwrVgmSqZek0mjAmRiVzIC_IuhGfGmORCviUXotCKS11MyN8lBHxy1LiGft-5uEnXQH1LH4wbA31EZwJQQacP80dxdcBWGKJ3QJdgLMRutwemq-V8cUVvMGzBYouW3rsN1hj9EOhNIhrqHf1m7IARHdYHo9vf2ICzsB-3HE2X-nHzx-zOWkwSdHQFvYm-809oE7OArqNrdBDekzet6QJ8OJ2X5OeX2x-LVbb-ene_mK8zI1UZM85yZYTkDeOgSi1V0bZ5LkwLOpVag2SWq-tUC95oqUstOIAqjJTC8LS8SzI9-m4H_2uEEKseg03PMA78GCpeCpkWy_LrhKojagcfwgBttR2wN8Ou4qzap1al1KpzatUptST7dJow1qn3IjrHlAB2BA5yPw4uffj_nv8AAjel_g</recordid><startdate>20160922</startdate><enddate>20160922</enddate><creator>Yang, Eugene Guorong</creator><creator>Mustafa, Nurulhuda</creator><creator>Tan, Eng Chong</creator><creator>Poulsen, Anders</creator><creator>Ramanujulu, Pondy Murugappan</creator><creator>Chng, Wee Joo</creator><creator>Yen, Jeffrey J. Y</creator><creator>Dymock, Brian W</creator><general>American Chemical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160922</creationdate><title>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</title><author>Yang, Eugene Guorong ; Mustafa, Nurulhuda ; Tan, Eng Chong ; Poulsen, Anders ; Ramanujulu, Pondy Murugappan ; Chng, Wee Joo ; Yen, Jeffrey J. Y ; Dymock, Brian W</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Bridged-Ring Compounds - chemistry</topic><topic>Bridged-Ring Compounds - pharmacology</topic><topic>Cell Line, Tumor</topic><topic>Cell Proliferation - drug effects</topic><topic>Hematologic Neoplasms - drug therapy</topic><topic>Hematologic Neoplasms - metabolism</topic><topic>Histone Deacetylase Inhibitors - chemistry</topic><topic>Histone Deacetylase Inhibitors - pharmacology</topic><topic>Humans</topic><topic>Janus Kinase 2 - antagonists &amp; inhibitors</topic><topic>Models, Molecular</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Pyrimidines - chemistry</topic><topic>Pyrimidines - pharmacology</topic><topic>Signal Transduction - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Eugene Guorong</creatorcontrib><creatorcontrib>Mustafa, Nurulhuda</creatorcontrib><creatorcontrib>Tan, Eng Chong</creatorcontrib><creatorcontrib>Poulsen, Anders</creatorcontrib><creatorcontrib>Ramanujulu, Pondy Murugappan</creatorcontrib><creatorcontrib>Chng, Wee Joo</creatorcontrib><creatorcontrib>Yen, Jeffrey J. Y</creatorcontrib><creatorcontrib>Dymock, Brian W</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Eugene Guorong</au><au>Mustafa, Nurulhuda</au><au>Tan, Eng Chong</au><au>Poulsen, Anders</au><au>Ramanujulu, Pondy Murugappan</au><au>Chng, Wee Joo</au><au>Yen, Jeffrey J. Y</au><au>Dymock, Brian W</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2016-09-22</date><risdate>2016</risdate><volume>59</volume><issue>18</issue><spage>8233</spage><epage>8262</epage><pages>8233-8262</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>Blockage of more than one oncoprotein or pathway is now a standard approach in modern cancer therapy. Multiple inhibition is typically achieved with two or more drugs. Herein, we describe a pharmacophore merging strategy combining the JAK2/FLT3 inhibitor pacritnib with the pan-HDAC inhibitor, vorinostat, to create bispecific single molecules with both JAK and HDAC targeted inhibition. A preferred ether hydroxamate, 51, inhibits JAK2 and HDAC6 with low nanomolar potency, is &lt;100 nM potent against HDACs 2 and 10, submicromolar potent against HDACs 1, 8, and 11, and &gt;50-fold selective for JAK2 in a panel of 97 kinases. Broad cellular antiproliferative potency is supported by demonstration of JAK-STAT and HDAC pathway blockade in several hematological cell lines, inhibition of colony formation in HEL cells, and analysis of apoptosis. This study provides new tool compounds for further exploration of dual JAK–HDAC pathway inhibiton achieved with a single molecule.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>27541357</pmid><doi>10.1021/acs.jmedchem.6b00157</doi><tpages>30</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2016-09, Vol.59 (18), p.8233-8262
issn 0022-2623
1520-4804
language eng
recordid cdi_proquest_miscellaneous_1823031069
source American Chemical Society:Jisc Collections:American Chemical Society Read & Publish Agreement 2022-2024 (Reading list)
subjects Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Apoptosis - drug effects
Bridged-Ring Compounds - chemistry
Bridged-Ring Compounds - pharmacology
Cell Line, Tumor
Cell Proliferation - drug effects
Hematologic Neoplasms - drug therapy
Hematologic Neoplasms - metabolism
Histone Deacetylase Inhibitors - chemistry
Histone Deacetylase Inhibitors - pharmacology
Humans
Janus Kinase 2 - antagonists & inhibitors
Models, Molecular
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Pyrimidines - chemistry
Pyrimidines - pharmacology
Signal Transduction - drug effects
title Design and Synthesis of Janus Kinase 2 (JAK2) and Histone Deacetlyase (HDAC) Bispecific Inhibitors Based on Pacritinib and Evidence of Dual Pathway Inhibition in Hematological Cell Lines
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T06%3A22%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20and%20Synthesis%20of%20Janus%20Kinase%202%20(JAK2)%20and%20Histone%20Deacetlyase%20(HDAC)%20Bispecific%20Inhibitors%20Based%20on%20Pacritinib%20and%20Evidence%20of%20Dual%20Pathway%20Inhibition%20in%20Hematological%20Cell%20Lines&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Yang,%20Eugene%20Guorong&rft.date=2016-09-22&rft.volume=59&rft.issue=18&rft.spage=8233&rft.epage=8262&rft.pages=8233-8262&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/acs.jmedchem.6b00157&rft_dat=%3Cproquest_cross%3E1823031069%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a348t-1064a231d01e485347ff662afe52afb5e30c14930c71d5358521ee47a332a1623%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1823031069&rft_id=info:pmid/27541357&rfr_iscdi=true